For safety and efficacy in targeted abdominal MR Imaging

Clinical studies

Phase I
  • Gentofte University Hospital, Gentofte, Denmark
    Investigator, Professor Jesper Sonne
Phase II
  • University Hospital, Nijmegen, the Netherlands
    Investigator, Professor Jelle Barentz
  • Karolinska University Hospital, Huddinge, Sweden
    Investigators, Professor Peter Aspelin, Professors Nils Albiin and Torkel Brismar
  • Charité University Hospital, Berlin, Germany
    Investigators, Professor Bert Ham and Professor M Taupitz
  • Sahlgren University Hospital, Gothenburg, Sweden
    Investigators, Professor Mikael Hellström and Professor Mats Andersson
Use under

“Compassionate use program” Copenhagen University Hospital, Herlev, Denmark

Current total number of patients in different clinical programs is approximately 200.

About CMC Contrast

100% owned and financed by professional venture capital companies specializing in life sciences and dedicated to contrast agents

Learn more
Medical background

CMC 001 delivers manganese orally, resulting in excellent liver enhancement in MRI.

Medical background
Benefits for your team

Using CMC 001 creates advantages for the staff, and saves time and cost.

More Benefits
CMC Contrast AB, Ideon, SE-223 70 Lund. Telephone +46 46 286 37 60. E-mail: info@cmc-contrast.se